Richard B. Kim, MD, FRCPC, Division Chair
Dr. Kim received his medical degree from University of Saskatchewan, Canada in 1987. After completing an internship and residency training at Royal University hospital in Saskatoon Canada in 1991, he went on to carry out postdoctoral fellowship training in Clinical Pharmacology at Vanderbilt University.
In 1994, upon completion of his fellowship training, he remained at Vanderbilt Clinical Pharmacology as a faculty member until 2006. He is currently Professor and Chair of the Division of Clinical Pharmacology in the Department of Medicine at the University of Western Ontario in London, Canada. His research interest is that of understanding the molecular basis of interindividual differences in drug disposition and the application of such finding to the emerging field of Personalized Medicine.
Research areas under active investigation in his laboratory include that of drug transporters, CYP enzymes, and the pathways involved in the regulated expression of such proteins. He is a member of ASCPT, ISSX, and AAPS. He is an editor for the Medical Letter Handbook of Adverse Drug Interactions, and an associate editor for Molecular Pharmacology. He is a fellow of AAPS, and member of the American Society for Clinical Investigation (ASCI).

Publications
2005  2006  2007  2008  2009
<<<        >

Dixit S., Tirona R.G., and Kim R.B.: Beyond CAR and PXR. Curr Drug Metab 6:385-397, 2005. [Pubmed]

Dresser G.K., Kim R.B., and Bailey D.G.: Effect of grapefruit juice volume on the reduction of fexofenadine bioavailability: possible role of organic anion transporting polypeptides. Clin. Pharmacol. Ther., 77:170-177, 2005.  [Pubmed]

Haas D.W., Smeaton L.M., Shafer R.W., Robbins G.K., Morse G.D., Labbe L., Wilkinson G.R., Cliffort D.B., D�Aqulia R.T., De Gruttola V., Pollard R.B., Merigan T.C., Hrisch M.S., George A.L., Donahue J.P., and Kim R.B.: Pharmacogenetics of long-term responses to efavirenz- and nelfinvir-containing antiviral regimens: An adult AIDS clinical trials group study. J. Infect. Dis. 192:1931-1942, 2005. [Pubmed]

Ho R.H., and Kim R.B.: Transporters and drug therapy: implications for drug disposition and disease. Clin. Pharmacol. Ther. 78: 260-277, 2005 [Pubmed]

Lee W., Glaeser H., Smith L.H., Roberts R.L., Moeckel G.W., Gervasini G., Leake B.F., and Kim R.B.: Polymorphisms in human organic anion transporting polypeptide 1A2: Implications for altered drug disposition and CNS drug entry. J. Biol. Chem., 280:9610-9617, 2005. [Pubmed]

Lee W., Lockhart A.C., Kim R.B., and Rothenberg M.L.: Cancer pharmacogenomics: Powerful tools in cancer chemotherapy and drug development. Oncologist, 10:104-111, 2005. [Pubmed]

Marzolini C., and Kim R.B.: Placental transfer of antiretroviral drugs. Clin. Pharmacol. Ther.78:118-122, 2005 [Pubmed]

Sandhu P., Lee W., Xu X., Leake B.F., Yamazaki M., Stone J.A., Lin J.H., Pearson P.G., and Kim R.B.: Hepatic uptake of the novel antifungal agent caspofungin. Drug Met. Disp., 33: 676-682, 2005. [Pubmed]

Schwarz U.I., Seemann D., Oertel R., Miehlke S., Kuhlisch E., Fromm M.F., Kim R.B., Bailey D.G., and Kirch W.: Grapefruit juice ingestion significantly reduces talinolol bioavailability. Clin. Pharmacol. Ther., 77:291-301, 2005. [Pubmed]

Simard C., Drolet B., Yang P., Kim R.B., and Roden D.M.: Polymorphism screening in the cardiac K+ channel gene KCNA5. Clin. Pharmacol. Ther., 77:138-144, 2005. [Pubmed]

Tirona R.G., and Kim R.B.: Nuclear receptors and drug disposition gene regulation. J. Pharm. Sci., 94: 1169-86. 2005 [Pubmed]

Xie H.G., and Kim R.B.: St Johnâ??s wort-associated drug interactions: short-term inhibition and long-term induction? Clin. Pharmacol. Ther. 78:19-24, 2005 [Pubmed]

Xu H., Rajesan R., Harper P., Kim R.B., Lonnerdal B., Yang M., Uematsu S., Hutson J., Watson-Macdonell J., and Ito S.: Induction of cytochrome P450 1A by cow milk-based formula: a comparative study between human milk and formula. Br. J. Pharmacol. 146:296-305, 2005. [Pubmed]